In vitro growth inhibition of bloodstream forms of Trypanosoma brucei and Trypanosoma congolenseby iron chelators

Kinetoplastid Biology and Disease - Tập 5 - Trang 1-5 - 2006
Karin Merschjohann1, Dietmar Steverding1,2
1Department of Parasitology, Ruprecht-Karls-University, Heidelberg, Germany
2BioMedical Research Centre, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK

Tóm tắt

African trypanosomes exert significant morbidity and mortality in man and livestock. Only a few drugs are available for the treatment of trypanosome infections and therefore, the development of new anti-trypanosomal agents is required. Previously it has been shown that bloodstream-form trypanosomes are sensitive to the iron chelator deferoxamine. In this study the effect of 13 iron chelators on the growth of Trypanosoma brucei, T. congolense and human HL-60 cells was tested in vitro. With the exception of 2 compounds, all chelators exhibited anti-trypanosomal activities, with 50% inhibitory concentration (IC50) values ranging between 2.1 – 220 μM. However, the iron chelators also displayed cytotoxicity towards human HL-60 cells and therefore, only less favourable selectivity indices compared to commercially available drugs. Interfering with iron metabolism may be a new strategy in the treatment of trypanosome infections. More specifically, lipophilic iron-chelating agents may serve as lead compounds for novel anti-trypanosomal drug development.

Tài liệu tham khảo

World Health Organization: African trypanosomiasis or sleeping sickness. World Health Organ Fact Sheet. 2001, 259: [http://www.who.int/mediacentre/factsheets/fs259/en/] World Health Organization: The world health report 2004: changing history. Geneva. 2004 Kristjanson PM, Swallow BM, Rowlands GJ, Kruska RL, de Leeuw PN: Measuring the costs of African animal trypanosomiasis, the potential benefits of control and returns to research. Agr Sys. 1999, 59: 79-98. 10.1016/S0308-521X(98)00086-9. Croft SL: The current status of antiparasitic chemotherapy. Parasitology. 1997, 114 (Suppl): S3-S15. Fairlamb AH: Chemotherapy of human African trypanosomiasis: current status and future prospects. Trends Parasitol. 2003, 19: 488-494. 10.1016/j.pt.2003.09.002. Ross CA, Sutherland DV: Drug resistance in trypamosomatids. Trypanosomiasis and Leishmaniasis: Biology and Control. Edited by: Hide G, Mottram JC, Coombs GH, Holmes PH. 1997, Wallingford, Oxon: CAB International, 259-269. Matovu E, Seebeck T, Enyaru JCK, Kaminsky R: Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect. 2001, 3: 763-770. 10.1016/S1286-4579(01)01432-0. Steverding D: Bloodstream forms of Trypanosoma brucei require only small amounts of iron for growth. Parasitol Res. 1998, 84: 59-62. 10.1007/s004360050357. Breidbach T, Scory S, Krauth-Siegel RL, Steverding D: Growth inhibition of bloodstream forms of Trypanosoma brucei by the iron chelator deferoxamine. Int J Parasitol. 2002, 32: 473-479. 10.1016/S0020-7519(01)00310-1. Räz B, Iten M, Grether-Bühler Y, Kaminisky R, Brun R: The Alamar Blue® assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop. 1997, 68: 139-147. 10.1016/S0001-706X(97)00079-X. Merschjohann K, Sporer F, Steverding D, Wink M: In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense. Planta Med. 2001, 67: 623-627. 10.1055/s-2001-17351. Winkelmann G: Microbial siderophore-mediated transport. Biochem Soc Trans. 2002, 30: 691-696. 10.1042/BST0300691. Peterson CM, Graziano JH, Grady RW, Jones RL, Vlassara HV, Canale VC, Miller DR, Cerami A: Chelation studies with 2,3-dihydroxybenzoic acid in patients with β-thalassaemia major. Br J Haematol. 1976, 33: 477-485. Salamah AA: Effect of ethylenediamine di-o-hydroxyphenylacetic acid and transferrin on the growth of some bacterial strains in vitro. Microbiologica. 1992, 15: 361-366. Deterding A, Dungey FA, Thompson K-T, Steverding D: Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Trop. 2005, 93: 311-316. 10.1016/j.actatropica.2005.01.005. White GP, Jacobs A, Grady RW, Cerami A: The effect ofchelating agents on iron mobilization in Chang cell cultures. Blood. 1976, 48: 923-929. Burgess J, Drasdo DN, Patel MS: Solubilities and solvation of aluminum(III), iron(III), and indium(III) 8-hydroxyquinolinates in methanol/water mixtures. J Pharm Sci. 1994, 83: 54-7. Boadi WY, Iyere PA, Adunyah SE: Effect of quercetin and genistein on copper- and iron-induced lipid peroxidation in methyl linolenate. J Appl Toxicol. 2003, 23: 363-369. 10.1002/jat.933. Romeo AM, Christen L, Niles EG, Kosman DJ: Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools. J Biol Chem. 2001, 276: 24301-24308. 10.1074/jbc.M010806200. Mudasir , Wijaya K, Yoshioka N, Inoue H: DNA binding of iron(II) complexes with 1,10-phenanthroline and 4,7-diphenyl-1,10-phenanthroline: salt effect, ligand substituent effect, base pair specificity and binding strength. J Inorg Biochem. 2003, 94: 263-271. 10.1016/S0162-0134(03)00007-2. Buss JL, Greene BT, Turner J, Torti FM, Torti SV: Iron chelators in cancer chemotherapy. Curr Top Med Chem. 2004, 4: 1623-1635. 10.2174/1568026043387269. Richardson DR: Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr Med Chem. 2005, 12: 2711-2729. 10.2174/092986705774462996. Pahl PM, Horwitz LD: Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest. 2005, 23: 683-691. 10.1080/07357900500359976. Hirumi H, Hirumi K, Doyle JJ, Cross GAM: In vitro cloning of animal-infective bloodstream forms of Trypanosoma brucei. Parasitology. 1980, 80: 371-382. Kaminsky R, Schmid C, Grether Y, Holý A, De Clercq E, Naesens L, Brun R: (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]: a purine analogue with trypanocidal activity in vitro and in vivo. Trop Med Int Health. 1996, 1: 255-263. Baltz T, Baltz D, Giroud C, Crockett J: Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J. 1985, 4: 1273-1277. Huber W, Koella JC: A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop. 1993, 55: 257-261. 10.1016/0001-706X(93)90083-N.